OT mobile menu



Slide Show: Trends in Targeted Therapies and Immunotherapies

Check out our slide show on current trends in targeted therapies and immunotherapies


Image © Anita Ponne/ Shutterstock.com.
Image © Anita Ponne/ Shutterstock.com.
Image © Anita Ponne/ Shutterstock.com.
Image © Blamb / Shutterstock.com.
Image © Blamb / Shutterstock.com.
Image © Blamb / Shutterstock.com.
Nivolumab showed greater overall survival in patients with metastatic squamous NSCLC, - See more at: http://www.oncotherapynetwork.com/asco-2015/nivolumab-improves-response-...

Recent Content

A new three-pronged approach may help better identify patients who have Lynch syndrome, an inherited cancer susceptibility syndrome that predisposes individuals to various cancers, according to researchers at Baylor College of Medicine.

Patients with renal cell carcinoma (RCC) who have not responded to prior therapy may soon have a new treatment option.

A recent study shows that the investigational drug EP-100--a synthetic cytolytic peptide conjugated to a luteinizing hormone releasing hormone (LHRH) -- may be a treatment option for taxane-resistant ovarian cancer.

Findings published in the current issue of Cancer Cell show that a newly-identified lipid phosphatase gene, proline-rich inositol polyphosphate 5-phosphatase, or PIPP (INPP5J), is involved in primary breast tumor initiation and growth.

The novel investigational DNA methylation-inhibiting agent guadecitabine (SGI-110) is “well-tolerated, easily administered, and biologically and clinically active” in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

A protein called CSN6 has been found to be correlated with poor survival among patients with colorectal cancer.

Roche’s investigational immunotherapy agent atezolizumab (MPDL3280A; anti-PDL1) achieved an objective response rate in the pivotal phase II BIRCH safety and efficacy trial, shrinking tumors among patients with programmed death ligand-1 (PDL1)-expressing non-small cell lung cancer (NSCLC).

By clicking Accept, you agree to become a member of the UBM Medica Community.